PAWC
P.A.W. Capital Portfolio holdings
AUM
$51.9M
This Quarter Return
+8.61%
1 Year Return
+46.14%
3 Year Return
+74.13%
5 Year Return
+167.35%
10 Year Return
+839.74%
AUM
$92.8M
AUM Growth
+$92.8M
(+1.5%)
Cap. Flow
-$5.71M
Cap. Flow
% of AUM
-6.15%
Top 10 Holdings %
Top 10 Hldgs %
41.51%
Holding
71
New
7
Increased
6
Reduced
17
Closed
5
Top Buys
| 1 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$1.4M |
| 2 |
Magnite
MGNI
|
$1.08M |
| 3 |
Exicure
XCUR
|
$818K |
| 4 |
Krystal Biotech
KRYS
|
$527K |
| 5 |
Cue Biopharma
CUE
|
$453K |
Top Sells
| 1 |
Semler Scientific
SMLR
|
$1.69M |
| 2 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$1.32M |
| 3 |
ATTU
Attunity Ltd
ATTU
|
$1.13M |
| 4 |
Akebia Therapeutics
AKBA
|
$998K |
| 5 |
Galapagos
GLPG
|
$830K |
Sector Composition
| 1 | Technology | 32.83% |
| 2 | Healthcare | 16.66% |
| 3 | Communication Services | 15.02% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Staples | 10.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CCXI
26
DELISTED
ChemoCentryx, Inc.
CCXI
| $1.14M | 1.21% |
90,000
+5,000
| +6% | +$63.2K |
|
|
CLLS
27
Cellectis
CLLS
$258M
| $1.13M | 1.2% |
40,000
| – | – |
|
|
28
Magnite
MGNI
$3.7B
| $1.08M | 1.15% |
+300,000
| New | +$1.08M |
|
29
New Mountain Finance
NMFC
$1.13B
| $1.08M | 1.15% |
80,000
-15,000
| -16% | -$203K |
|
30
AT&T
T
$209B
| $840K | 0.89% |
25,000
-20,000
| -44% | -$672K |
|
|
31
Exicure
XCUR
$35.4M
| $818K | 0.87% |
+200,000
| New | +$818K |
|
|
RDS.A
32
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
| $818K | 0.87% |
12,000
| – | – |
|
33
Verizon
VZ
$186B
| $801K | 0.85% |
15,000
| – | – |
|
34
Johnson & Johnson
JNJ
$427B
| $760K | 0.81% |
5,500
| – | – |
|
35
Abbott
ABT
$231B
| $734K | 0.78% |
10,000
| – | – |
|
|
36
Cue Biopharma
CUE
$60M
| $724K | 0.77% |
80,000
+50,000
| +167% | +$453K |
|
37
Altria Group
MO
$113B
| $724K | 0.77% |
12,000
| – | – |
|
38
Merck
MRK
$210B
| $709K | 0.75% |
10,000
-1,000
| -9% | -$70.9K |
|
39
Pfizer
PFE
$141B
| $705K | 0.75% |
16,000
-2,000
| -11% | -$88.1K |
|
40
Coca-Cola
KO
$297B
| $693K | 0.74% |
15,000
| – | – |
|
41
BP
BP
$90.8B
| $692K | 0.73% |
15,000
+1,000
| +7% | +$46.1K |
|
42
PepsiCo
PEP
$204B
| $671K | 0.71% |
6,000
| – | – |
|
43
Procter & Gamble
PG
$368B
| $666K | 0.71% |
8,000
| – | – |
|
44
Omega Healthcare
OHI
$12.6B
| $655K | 0.7% |
20,000
| – | – |
|
45
Philip Morris
PM
$260B
| $652K | 0.69% |
8,000
| – | – |
|
46
TotalEnergies
TTE
$137B
| $644K | 0.68% |
10,000
| – | – |
|
47
DuPont de Nemours
DD
$32.2B
| $643K | 0.68% |
10,000
| – | – |
|
48
GSK
GSK
$79.9B
| $643K | 0.68% |
16,000
| – | – |
|
49
Exxon Mobil
XOM
$487B
| $638K | 0.68% |
7,500
| – | – |
|
50
AbbVie
ABBV
$372B
| $615K | 0.65% |
6,500
| – | – |
|